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A human neurotensin receptor (hNTR) cDNA was cloned from the colonic adenocarcinoma cell line HT29. The cloned cDNA encodes a putative 
peptide of 418 amino acids with 7 transmembrane domains. The amino acid sequence of the hNTR is 84% identical to the rat NTR meuron, 4 
(1990) 847-8541. Transfection of this cDNA into COS cells results in the expression of receptors with pharmacological properties imilar to those 
found with HT29 cells. Northern blot analysis using the hNTR cDNA probe indicated a single transcript of 4 kb in the brain, the small intestine 
and blood mononuclear cells. 
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1. INTRODUCTION 
Neurotensin (NT) is a tridecapeptide originally iso- 
lated from calf hypothalamus [l]. Thereafter, the pres- 
ence of high concentrations of neurotensin was found 
in numerous areas of the central nervous system (CNS) 
and gastro-intestinal tissues [2]. In these tissues, neuro- 
tensin produces a diversity of pharmacological effects 
[3]. Evidence of a close connection between the NT and 
dopaminergic systems has recently increased the interest 
for NT-containing circuits considering their potential 
implications in abnormal behavior and neuropsychia- 
tric disorders [4]. 
The pharmacological effects displayed by neuroten- 
sin are mediated by specific membrane receptors. The 
biochemical and pharmacological properties of these 
binding sites have been extensively studied using mam- 
malian brain homogenates as well as membrane prepa- 
rations from neuronal and certain non-neuronal cell 
lines [5,6]. It has been shown that the interaction with 
these receptors modulates intracellular levels of cGMP, 
CAMP and inositol phosphates [7,8]. 
Different groups were able to solubilize and purify to 
homogeneity NT receptors (NTRs) from bovine [9], rat 
[lo] and mouse brains [I 1,121, and more recently, 
Tanaka et al. [13] reported the molecular cloning of the 
rat neurotensin receptor. 
In the present study, a cDNA encoding the human 
neurotensin receptor was isolated by screening a human 
colon adenocarcinoma cell line (HT-29) cDNA expres- 
sion library using a radioligand-binding strategy. This 
cDNA encodes a 418 amino-acid protein with a trans- 
membrane topology similar to that of other G-protein 
coupled receptors. The properties of the cloned binding 
site expressed in COS cells are identical to those found 
in HT29 cells. In addition, besides the small intestine 
and brain, the expression of neurotensin receptor 
mRNAs was also detected in peripheral blood mononu- 
clear cells (PBMC). 
2. MATERIALS AND METHODS 
2.1. Drugs und peptides 
Labeled (?-labeled [monoiodo-Ty?]neurotensin, 2 000 Wmmol) 
and unlabeled neurotensin were purchased from Amersham (Bucking- 
hamshire, UK) and Bachem (Bubendorf, Switzerland), respectively. 
Dulbecco’s modified essential medium (DMEM), fetal calf serum 
(FCS) and phosphate-buffered saline (PBS) were from Gibco (Paisley, 
Scotland). Bovine serum albumin (BSA), phenylmethylsulfon- 
ylfluoride (PMSF) and l,lO-orthophenanthroline were from Sigma 
(St. Louis, MO). 
A selective, non-peptide antagonist SR 48692 was synthesized at 
Sanofi Recherche, Montpellier, France [14]. The anti-histamine agent, 
levocabastine, was obtained from Janssens Pharmaceutics (Geel, Bel- 
glum). 
2.2. Cell culture 
The human colonic adenocarcinoma HT29 cell line (kindly pro- 
vided by Dr. P. Kitabgi) and the COS-7 cell line were cultured as 
previously described [8]. 
Correspondence address: D. Caput, Unite Biologic Moleculaire du 2.3. RNA extraction and analysis 
Gene, Sanofi Elf Biorecherches, BP 137,3 1676 Labege Cedex, France. Total RNA was extracted from HT29 cells by using the acid-guani- 
Fax: (33) (61) 39 86 37. dinium isothiocyanate-phenol-chloroform ethod [IS]. PoIy(A) 
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RNA was isolated from total RNA by oligo(dT)-cellulose chromatog- 
raphy as described by Aviv and Leder [16]. RNA analysts was per- 
formed by electrophoresis on 1% agarose/formadehyde g ls then 
transferred to nitrocellulose and probed with a “P-labeled hNTR 
cDNA as described [17]. 
2.4. cDNA library construction and DNA sequencing 
The cDNA library was constructed usmg the primer-adapter proce- 
dure [IS] and the pSVL vector (Pharmacia). Approximately 5 x 10’ 
primary recombinants were produced and organized in pools of 1,000 
clones. DNA sequences were dete~in~ by the method of Sanger 1191. 
2.5. Tru~s~ectlon of COS ceils and rad~o~abe~ed ligand detection 
Preparatton of recombinant plasmids and the transfection of COS-7 
cells by the DEAE dextran procedure were as previously described 
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Fig. 1. Nucleottde and predicted amino acid sequences of the hNTR 
cDNA. 
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Fig. 2. Ahgnment of the hNTR to the rNTR. The complete hNTR and 
rNTR sequences are compared; gaps for alignment are indicated by 
dots and identical residues indicated by vertical ines. The solid lines 
above the sequences indicate the proposed transmembrane domains 
[20]. Briefly, 5 x IO5 cells were plated in Shdes Flasks (Nunc) and 
grown in DMEM containing 5% FCS in 5% CO, at 37°C. After an 
overnight Incubation, the cells were transfected with 3 pig of extracted 
DNA from pools in 2 ml of DMEM containing 400 mg of DEAE 
dextran (Pharmacia) and 200 PM of chloroquine diphosphate. After 
5 h at 37’C, the transfecting medium was removed and the cells were 
treated with 2 ml of PBS cont~ning 10% DMSO for 1 min. rinsed 
twice with PBS and incubated in DMEM ~onta~nlng 1% FCS for 3 
days. Receptor-expressing pools were detected by binding using “‘I- 
labeled [monoiodo-Tyr3]neurotensin (see below) as a probe followed 
by autoradiography using a Phospholmager device (Molecular Dy- 
namics, Sunnyvale, CA). 
2.6, Bmdmg experiments 
The pharmacological nd functional characterization of the cloned 
receptor was performed using COS-transfected cells seeded in 6-well 
plates (Falcon). Three days after transfection, cell monolayers were 
washed twice with 50 mM Tris-HCI pH 7.5. 0.2% BSA, 0.1% NaN,. 
1 mM l.lO-orr~o-phenanthroline (binding buffer). 
Saturation experiments were done in 1.5 ml of binding buffer con- 
tammg ‘251-labeled [monolodo-Tyr3]neurotensin over a range from 
0 05 to 2 nM in the absence or in the presence of a 500-fold excess of 
unlabeled neurotensin. After I h incubation at room temperature, 
plates were aspirated and cell monolayers were washed twice with 
mcubatton buffer. Finally, 2 ml of 1 N NaOH were added and bound 
radioactivity was quantified after cell solubilisation. Non-specific 
bindmg was defined as bmding in the presence of a 500-fold excess of 
unlabeled hgand and under these expertmental conditions was < 1% 
of the total counts. 
Displacement experiments were done m an analogous manner usmg 
0.2 nM of “‘l-labeled [monoiodo-Tyr’lneurotensin as radtoligand. 
The following unlabeled ligands were used as competitors: neuroten- 
sin, neuromedin N, SR 48692 and levocabastine. 
Bindmg data derived from saturation and competition experiments 
were analysed by usmg the computerized nonlinear curve fitting de- 
scribed by Munson and Rodbard [21]. 
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Fig. 3. Saturation isotherm and Scatchard plot (inset) of the specific 
binding of “51-labeled [monoiodo-Tyr3]neurotensin to COS-7 cells 
transfected with the hNTR cDNA. Each point represents the mean of 
triplicates. 
3. RESULTS AND DISCUSSION 
3.1. Cloning and sequencing of hNTR 
A cDNA expression library containing 5 x 10’ re- 
combinant clones was constructed and divided into 
pools of lo3 clones. Plasmid DNA from each pool was 
introduced into COS cells and the binding of neuroten- 
sin was detected with a labeled ligand. Only one of the 
first hundred pools tested showed a significant binding 
activity. Stepwise fractionations of this neurotensin re- 
ceptor cDNA-containing pool identified a single recom- 
binant plasmid able to confer a neurotensin binding 
activity to COS cells. 
Fig. 1 shows the 4,140-nucleotide sequence of hNTR 
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Fig. 4. Inhibition of ‘251-labeled [monoiodo-Tyr3]neurotensin b ding 
to COS-7 cells transfected with the hNTR cDNA by unlabeled neuro- 
tensin (o), neuromedin N (o), SR 48692 (A) and levocabastme (A). 
Each point represents the mean of triplicates. 
cDNA. Considering the determined size of the NTR 
mRNA (Fig. 5) hNTR cDNA seems to represent a full 
length transcript. The longest open reading frame found 
encodes a protein of 418 residues with a theoretical 
molecular weight of 46,288 kDa. The protein shows 
several structural features of G-protein coupled recep- 
tors and a high degree of identity (84%) and similarity 
(92%) with the rat neurotensin receptor [13] (Fig. 2). 
3.2. Pharmacological and functional characterization of 
cloned hNTR 
We have examined the binding properties of the 
human neurotensin receptor expressed in COS cells 
after transfection of the cloned cDNA. Little or no 
3 5 
Fig. 5. Northern analysis of poly(A) RNA (Ipug) from cells and tissues hybridized to 32P-labeled hNTR cDNA. Lane 1, HT29 cells; lane 2, human 
brain (rear part); lane 3. human brain (front part); lane 4, intestine: lane 5, PBMC. 
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binding was detected with untransfected cells or cells 
transfected with the vector DNA alone (not shown). 
The expressed receptor is able to bind in a specific 
and saturable manner ‘*‘I-labeled [monoiodo- 
Tyr3]neurotensin (Fig. 3). Scatchard plot analysis of 
‘251-labeled [monoiodo-Tyr3]neurotensin binding (Fig. 
3, inset) showed a single high affinity population of 
receptors with a dissociation constant (KJ of 0.56 k 0.1 
nM and a binding capacity (B,,,) of 30,000 k 3,000 
sites/cell. 
Fig. 4 shows competition curves of various ligands 
with ‘251-labeled [monoiodo-Tyr3]neurotensin. Agonists 
and antagonists competed for the binding of 
[monoiodo-Tyr3]neurotensin with an order of potency 
identical to the neurotensin receptor expressed in the 
HT29 cell line [6] and other tissues [14]: (i) neurotensin 
is the most potent competitor, followed by neuromedin 
N and SR 48692; (ii) the apparent half maximal concen- 
trations for an inhibition (IC,,) derived from the compe- 
tition curves were 0.3, 2.6 and 38 nM, respectively; and 
(iii) levocabastine, an anti-histamine agent described as 
a ligand for the low affinity neurotensin binding site [22] 
does not compete (using concentrations up to 10 PM) 
with “SI-labeled [monoiodo-Tyr3] neurotensin for the 
binding to COS cells, demonstrating that the transfected 
cDNA encodes a high affinity NTR. 
3.3. Tissue distribution of hNTR mRNA 
The tissue distribution of hNTR mRNA was exam- 
ined by Northern blot analysis. As shown in Fig. 5, 
32P-labeled hNTR cDNA hybridized to poly (A) RNAs 
isolated from HT29 cells, brain, colon and peripheral 
blood mononuclear cells (PBMC) gave rise to a single 
band although it is barely detectable in the brain RNAs 
(lanes 2 and 3). This result was confirmed by polym- 
erase chain reaction (PCR) experiments (not shown). 
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